1 week Ago By Defense World Staff
Corebridge Financial Inc. lessened its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 5.
0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,430 shares of the company’s stock after selling 819 shares during the quarter. Corebridge Financial Inc.
’s holdings in Kiniksa Pharmaceuticals were worth $305,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds also recently made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth about $158,000.
Teacher Retirement System of Texas grew its position in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after acquiring an additional 719 shares during the period.
Globeflex Capital L P increased its stake in shares of Kiniksa Pharmaceuticals by 217.1% during the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock worth $1,752,000 after purchasing an additional 60,656 shares during the last quarter.
Raymond James Financial Inc. bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth approximately $3,955,000. Finally, Charles Schwab Investment Management Inc.
lifted its stake in Kiniksa Pharmaceuticals by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc.
now owns 122,019 shares of the company’s stock valued at $2,414,000 after purchasing an additional 32,393 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.
Insider ActivityIn other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.
45, for a total transaction of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.
60. The trade was a 25.44 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark Ragosa sold 8,879 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $23.
10, for a total transaction of $205,104.90. Following the completion of the transaction, the chief financial officer now directly owns 23,382 shares in the company, valued at $540,124.
20. The trade was a 27.52 % decrease in their position.
The disclosure for this sale can be found here. Insiders sold 93,766 shares of company stock worth $2,011,735 in the last three months. Corporate insiders own 54.
57% of the company’s stock. Analyst Upgrades and DowngradesA number of analysts have issued reports on the company. Wedbush reissued an “outperform” rating and issued a $34.
00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.
00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $37.
17.Read Our Latest Research Report on KNSAKiniksa Pharmaceuticals Stock PerformanceNASDAQ:KNSA opened at $18.65 on Friday.
Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.
15. The business’s fifty day moving average is $20.96 and its 200 day moving average is $21.
65. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -133.
20 and a beta of 0.31. Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th.
The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.
06). The firm had revenue of $122.50 million during the quarter, compared to analysts’ expectations of $123.
42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.
36%. The company’s quarterly revenue was up 46.9% compared to the same quarter last year.
During the same period in the previous year, the company posted $0.35 earnings per share. Equities analysts predict that Kiniksa Pharmaceuticals, Ltd.
will post -0.55 EPS for the current fiscal year. About Kiniksa Pharmaceuticals (Free Report)Kiniksa Pharmaceuticals, Ltd.
, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.Further ReadingFive stocks we like better than Kiniksa PharmaceuticalsHow to Buy Gold Stock and Invest in GoldJoby Aviation: Operational Momentum vs.
Market SentimentHow to Know Which Cryptocurrency to Buy: A Guide for InvestorsBroadcom’s Big Outperformance Shows Strength Amid Tariff DeclineHow to Profit From Value Investing Carvana: Can Turnaround Strength Outdrive Market Headwinds?Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report).
.
